MacroGenics
MGNX
147 hedge funds and large institutions have $259M invested in MacroGenics in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 53 increasing their positions, 48 reducing their positions, and 42 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 48
6.56% less ownership
Funds ownership: 103.83% → 97.27% (-6.6%)
10% less funds holding
Funds holding: 163 → 147 (-16)
36% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 42
42% less call options, than puts
Call options by funds: $1.14M | Put options by funds: $1.97M
73% less capital invested
Capital invested by funds: $954M → $259M (-$695M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$35.1M |
| 2 |
Millennium Management
New York
|
+$31.4M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$14.2M |
| 4 |
Two Sigma Investments
New York
|
+$11.8M |
| 5 |
Two Sigma Advisers
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$90.5M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$40.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$27.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.7M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$7.36M |
MGNX Hedge Fund Activity: Q2 2024 in Review
147 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in MacroGenics (MGNX) for Q2 2024, worth a combined $259M — down 73% from $954M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of MGNX and 27 opened new positions — a net loss of 15 holders — while 48 trimmed existing stakes and 53 added.
The largest buyer was Armistice Capital, adding an estimated $35.1M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $90.5M sold.
- 147 institutional investors held MacroGenics (MGNX) as of Q2 2024, down from 163 in Q1 2024.
- Funds reported $259M of MacroGenics stock for Q2 2024, down 73% quarter-over-quarter.
- 27 funds opened new MacroGenics positions in Q2 2024 and 42 closed out, a net change of -15 holders.
- The largest MacroGenics buyer in Q2 2024 was Armistice Capital, an estimated $35.1M added.
- The largest MacroGenics seller in Q2 2024 was Avoro Capital Advisors, an estimated $90.5M sold.
Based on aggregated 13F filings for Q2 2024.